---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000068"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-08-07T11:00:11+00:00"
generated_at: "2026-08-07T11:05:51.424820+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21

## Summary
- Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.
- Cortrophin Gel revenue $117.1M, +43.5% YoY; ILUVIEN down 16.1% to $18.7M on shipment timing.
- Adjusted non-GAAP EBITDA $71.6M (+32.4%); adjusted diluted EPS $2.21 vs $1.80 prior.
- FY26 total revenue guidance reaffirmed $1,080-1,140M; Cortrophin Gel guidance narrowed to $520-540M from $540-575M.
- Board authorized $100M share repurchase program through May 2029.

## SEC filing metadata
- accession: 0001023024-26-000068
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-08-07T11:00:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/0001023024-26-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/ani-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000068
- JSON: https://secwatch.observer/filing/0001023024-26-000068.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.